Nishino, Mizuki http://orcid.org/0000-0003-0275-0502
Wang, Xinan
Ricciuti, Biagio
Tseng, Shu-Chi
Park, Hyesun
Alessi, Joao V.
Vaz, Victor R.
Hatabu, Hiroto
Lin, Xihong
Christiani, David C.
Awad, Mark M.
Funding for this research was provided by:
NCI (R01CA203636, U01CA209414)
Article History
Received: 28 December 2022
Revised: 6 March 2023
Accepted: 7 March 2023
First Online: 26 April 2023
Declarations
:
: The scientific guarantor of this publication is Mizuki Nishino, MD MPH.
: Nishino: consultant to Daiichi Sankyo, AstraZeneca; research grant from Merck, Canon Medical Systems, AstraZeneca, Daiichi Sankyo.Tseng, Alessi, Wang, Park, Vaz, Ricciuti, Lin, Christiani: None.Hatabu: reserch funding from Canon Inc., Canon Medical Systems, and Konica-Minolta; consultant to Canon Medical Systems, and Mitsubishi Chemical Inc.Awad: consultant/advisory board: Genentech, Bristol-Myers Squibb, Merck, AstraZeneca, Maverick, Blueprint Medicine, Syndax, Ariad, Nektar, ArcherDX, Mirati, NextCure, Novartis, EMD Serono. Institutional research funding: from Bristol-Myers Squibb, AstraZeneca, Lilly, Genentech.
: Two of the authors have significant statistical expertise (Wang and Lin).
: Written informed consent was obtained from all patients in this study.
: Institutional Review Board approval was obtained.
: • retrospective• observational• performed at one institution